IO Biotech
Biotech companies face high risks; clinical trial failures or lack of funding can lead to bankruptcy despite significant investment. Strategic alternatives must be explored early.
IO Biotech was a Biotechnology startup founded in 2014 in USA. It raised $170M before collapsing in 2026 — 12 years of runway burned. IdeaProof's AI Failure Score: 0/100, driven by filed for chapter 7 bankruptcy. The shutdown affected employees, investors, and the broader Biotechnology ecosystem. This case study breaks down the timeline, root causes, competitors that won, and replicable lessons for founders validating similar ideas today.
Why did IO Biotech fail?
IO Biotech failed in 2026 after 12 years of operation, losing $170M in raised capital. The root cause was filed for chapter 7 bankruptcy. Key lesson: Biotech companies face high risks; clinical trial failures or lack of funding can lead to bankruptcy despite significant investment. Strategic alternatives must be explored early.
2014 → 2026
$170M
Biotechnology
USA
Full Analysis
IO Biotech, a clinical-stage biopharmaceutical company focused on cancer immunotherapies, ceased operations and filed for Chapter 7 bankruptcy on March 31, 2026. The company had raised significant funding, including a $100 million Series B round in 2021 and a $100 million IPO. Despite this, the company was unable to secure additional financing or achieve clinical milestones necessary to continue operations. The filing triggered an event of default on a €22.5 million loan from the European Investment Bank. All employees and officers were terminated, and the board of directors resigned. This highlights the extreme capital intensity and high-risk nature of drug development, where even substantial funding does not guarantee success.
Could This Failure Have Been Prevented?
IdeaProof's AI validates market demand, competitive positioning, and business model viability in minutes — catching the exact issues that sank IO Biotech.